Table 2:

PD-L1 antibody clones used stratified by region

Region	North America	Central & South America	Europe	Asia	Oceania	Africa and Middle East		World
	n=83	n=25	n=140	n=61	n=13	n=22	Comparison test	n=344
PD-L1 clone
22C3*	n=66	n=18	n=136	n=55	n=13	n=14	p†=0.03	n=302
Non used	21 (32%)	6 (33%)	43 (32%)	13 (24%)	9 (69%)	2 (14%)		94 (31%)
Used	45 (68%)	12 (67%)	93 (68%)	42 (76%)	4 (31%)	12 (86%)		208 (69%)
Clinical assay	28 (62%)	5 (42%)	50 (54%)	29 (69%)	1 (25%)	11 (92%)	p†=0.04	124 (60%)
LDT	17 (38%)	7 (58%)	43 (46%)	13 (31%)	3 (75%)	1 (8%)		84 (40%)
28.8*	n=66	n=18	n=136	n=55	n=13	n=14	p†=0.005	n=302
Non used	58 (88%)	10 (56%)	106 (78%)	39 (71%)	12 (92%)	14 (100%)		239 (79%)
Used	8 (12%)	8 (44%)	30 (22%)	16 (29%)	1 (8%)	0		63 (21%)
Clinical assay	8 (100%)	0	22 (73%)	12 (75%)	0	-	p†<0.0001	42 (67%)
LDT	0	8 (100%)	8 (27%)	4 (25%)	1 (100%)	-		21 (33%)
SP142*	n=66	n=18	n=136	n=55	n=13	n=14	p†=0.09	n=302
Non used	53 (80%)	10 (56%)	90 (66%)	34 (62%)	10 (77%)	12 (86%)		209 (69%)
Used	13 (20%)	8 (44%)	46 (34%)	21 (38%)	3 (23%)	2 (14%)		93 (31%)
Clinical assay	8 (62%)	5 (63%)	31 (67%)	10 (48%)	1 (33%)	2 (100%)	p†=0.46	57 (61%)
LDT	5 (38%)	3 (37%)	15 (33%)	11 (52%)	2 (67%)	0		36 (39%)
SP263*	n=66	n=18	n=136	n=55	n=13	n=14	p†=0.001	n=302
Non used	43 (65%)	7 (39%)	67 (49%)	20 (36%)	2 (15%)	10 (71%)		149 (49%)
Used	23 (35%)	11 (61%)	69 (51%)	35 (64%)	11 (85%)	4 (29%)		153 (51%)
Clinical assay	8 (35%)	5 (45%)	59 (86%)	24 (69%)	7 (64%)	4 (100%)	p†<0.0001	107 (70%)
LDT	15 (65%)	6 (55%)	10 (14%)	11 (31%)	4 (36%)	0		46 (30%)
E1L3N*	n=66	n=18	n=136	n=55	n=13	n=14	p†=0.28	n=302
Non used	54 (82%)	18 (100%)	111 (82%)	42 (76%)	12 (92%)	12 (86%)		249 (82%)
Used (LDT only)	12 (18%)	0	25 (18%)	13 (24%)	1 (8%)	2 (14%)		53 (18%)

p†: X2 or Fisher exact bilateral test; LDT: laboratory developed test;

^*the numbers indicate those of participants who responded to the specific question.